REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Company profile
Ticker
RGNX
Exchange
Website
CEO
Kenneth Mills
Employees
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
Former names
ReGenX Biosciences, LLC
SEC CIK
Corporate docs
Subsidiaries
REGENXBIO EU Limited ...
RGNX stock data
Analyst ratings and price targets
Current price
Average target
$41.67
Low target
$14.00
High target
$61.00
SVB Leerink
Maintains
$14.00
Morgan Stanley
Maintains
$50.00
Chardan Capital
Maintains
$61.00
Latest filings (excl ownership)
8-K
Regenxbio Announces Senior Leadership Promotions
10 Jan 23
S-3ASR
Automatic shelf registration
30 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
3 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
3 Aug 22
8-K
Jennifer Zachary Joins REGENXBIO Board of Directors
7 Jun 22
10-Q
2022 Q1
Quarterly report
4 May 22
8-K
REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights
4 May 22
DEFA14A
Additional proxy soliciting materials
7 Apr 22
Transcripts
RGNX
Earnings call transcript
2022 Q3
3 Nov 22
RGNX
Earnings call transcript
2022 Q2
5 Aug 22
RGNX
Earnings call transcript
2022 Q1
5 May 22
RGNX
Earnings call transcript
2021 Q4
2 Mar 22
RGNX
Earnings call transcript
2021 Q3
3 Nov 21
RGNX
Earnings call transcript
2021 Q2
10 Aug 21
RGNX
Earnings call transcript
2021 Q1
6 May 21
RGNX
Earnings call transcript
2020 Q4
2 Mar 21
RGNX
Earnings call transcript
2020 Q3
5 Nov 20
RGNX
Earnings call transcript
2020 Q2
6 Aug 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 120.57 mm | 120.57 mm | 120.57 mm | 120.57 mm | 120.57 mm | 120.57 mm |
| Cash burn (monthly) | 943.33 k | 9.10 mm | 25.16 mm | (no burn) | 16.82 mm | (no burn) |
| Cash used (since last report) | 3.85 mm | 37.11 mm | 102.65 mm | n/a | 68.61 mm | n/a |
| Cash remaining | 116.73 mm | 83.47 mm | 17.92 mm | n/a | 51.96 mm | n/a |
| Runway (months of cash) | 123.7 | 9.2 | 0.7 | n/a | 3.1 | n/a |
Institutional ownership, Q3 2022
78.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 176 |
| Opened positions | 29 |
| Closed positions | 14 |
| Increased positions | 65 |
| Reduced positions | 57 |
| 13F shares | Current |
|---|---|
| Total value | 936.92 mm |
| Total shares | 34.01 mm |
| Total puts | 44.30 k |
| Total calls | 68.20 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 6.55 mm | $173.15 mm |
| Vanguard | 4.27 mm | $112.79 mm |
| JPM JPMorgan Chase & Co. | 4.05 mm | $107.17 mm |
| Redmile | 1.92 mm | $50.67 mm |
| Kiser 2012 Gift Trust | 1.91 mm | $86.72 mm |
| RTW Investments | 1.85 mm | $48.77 mm |
| Dimensional Fund Advisors | 1.25 mm | $33.14 mm |
| Aquilo Capital Management | 967.68 k | $25.58 mm |
| Geode Capital Management | 707.57 k | $18.70 mm |
| First Manhattan | 705.73 k | $18.65 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Jan 23 | Olivier Danos | Common Stock | Grant | Acquire A | No | No | 0 | 65,930 | 0.00 | 92,950 |
| 3 Jan 23 | Olivier Danos | Common Stock | Payment of exercise | Dispose F | No | No | 22.68 | 2,058 | 46.68 k | 27,020 |
| 3 Jan 23 | Olivier Danos | Stock Options Common Stock | Grant | Acquire A | No | No | 22.25 | 52,986 | 1.18 mm | 52,986 |
| 3 Jan 23 | Patrick J. Christmas | Common Stock | Grant | Acquire A | No | No | 0 | 67,940 | 0.00 | 89,037 |
| 3 Jan 23 | Patrick J. Christmas | Common Stock | Payment of exercise | Dispose F | No | No | 22.68 | 1,843 | 41.80 k | 21,097 |
| 3 Jan 23 | Patrick J. Christmas | Stock Options Common Stock | Grant | Acquire A | No | No | 22.25 | 56,519 | 1.26 mm | 56,519 |
| 3 Jan 23 | Vasista Vittal | Common Stock | Grant | Acquire A | No | No | 0 | 46,174 | 0.00 | 180,001 |
| 3 Jan 23 | Vasista Vittal | Common Stock | Payment of exercise | Dispose F | No | No | 22.68 | 1,333 | 30.23 k | 133,827 |
| 3 Jan 23 | Vasista Vittal | Stock Options Common Stock | Grant | Acquire A | No | No | 22.25 | 66,233 | 1.47 mm | 66,233 |
| 3 Jan 23 | Curran Simpson | Common Stock | Grant | Acquire A | No | No | 0 | 67,945 | 0.00 | 92,985 |
News
REGENXBIO Announced Phase I/II Trial of RGX-202, Novel Gene Therapy Candidate For Duchenne Muscular Dystrophy, Is Active And Recruiting Patients
23 Jan 23
SVB Leerink Maintains Market Perform on Regenxbio, Lowers Price Target to $14
23 Jan 23
REGENXBIO Announces Completion Of Dosing In The Phase I/II Trial Of RGX-111 For The Treatment Of Severe MPS I
8 Dec 22
Looking Into Regenxbio's Return On Capital Employed
22 Nov 22
5 Analysts Have This to Say About Regenxbio
21 Nov 22
Press releases
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
23 Jan 23
REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS
9 Jan 23
REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease
21 Dec 22
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I
8 Dec 22